QL535 / Qilu Pharma, QLSF Biotherapeutics - LARVOL DELTA

QL535: A novel CD2-costimulating PSMA-targeted T-cell engager with dose-responsive efficacy in PDX models and a favorable GLP toxicology profile in NHP (AACR 2026) - "QL535 was overall well tolerated in non-human primates, with pharmacodynamic changes consistent with T-cell engager activity. These findings demonstrate that QL535 delivers potent PSMA-targeted cytotoxicity, sustains function under exhaustion-inducing conditions, drives dose-responsive antitumor activity in patient-derived xenograft models, and exhibits a favorable safety and pharmacology profile, supporting advancement toward clinical evaluation in PSMA-positive prostate cancer."

Clinical • IO biomarker • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CD2 • CD28 • CD8 • CRP • CXCL8 • IFNG • IL6 • TNFA

QL535, A novel CD2-costimulating T cell engager targeting PSMA-positive prostate cancer matching CD28 trispecific antibody in cytotoxicity, minimizing cytokine release and T-cell exhaustion (AACR 2025) - "In conclusion, QL535 is a novel trispecific T cell engager with improved anti-tumor efficacy and safety profile. These findings warrant further clinical investigation to evaluate its safety and efficacy in patients."

Trispecific • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CD2 • CD58 • CD8 • CXCL8 • FOLH1 • IFNG • IL6 • TNFA